We believe that the support we have created--we believe, with that support, we have a project and legislation that works within the procedural confines of the Wild and Scenic Rivers Act in a limited way.

I strongly support Senate bill S. 1134 as the best opportunity to achieve the required project authorization that will allow the construction of a new bridge over the St. Croix River.

Air service is incredibly important in my state.

Madam President, I rise today to discuss the urgent need to raise the debt limit. I wish to take this opportunity to remind my colleagues of our obligation to represent our constituents' best interests and those of our great Nation, for at…

Basically, we need a--the feeling is that, and I think Mr. Tomten would agree, that a new bridge is needed.

We want to preserve this act, and we want to preserve the intent that Senators Mondale and Gaylord Nelson had.

I just want to say that.

The existing bridge cannot be replaced, because it is protected as an historic bridge.

I really, I believe that the smaller, slower bridge would also require an exemption, a congressional exemption.

Congratulations, Ranking Member Paul--who is my mentee--did you know that? In the Senatorial mentor program.

This is part of the 7(a) process.

No new bridge could move forward in the Stillwater area without congressional action.

If Congress is going to move forward with authorizing this project, does the Park Service have any concerns that this bill does not address?

I believe that we are going to need, no matter what we do, we're going to need an exemption to the Wild and Scenic Rivers Act.

Stillwater needs a bridge, and it needs it now, or, it needs it to start very soon.

I believe that we can make the FDA processes more efficient, more predictable, and better support and reward biomedical innovation.

I think we can all agree that patient safety is a priority of Congress and a priority of the FDA.

I plan to work on the three policy issues that I touched on in my questions, communication between the FDA and the industry, unnecessarily restrictive conflict of interest rules, and the profit cap on humanitarian use devices.